申请人:EURO-CELTIQUE S.A.
公开号:EP1867644A1
公开(公告)日:2007-12-19
A compound of formula:
where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a "Tetrahydropiperidyl Compound"); compositions comprising an effective amount of a Tetrahydropiperidyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Tetrahydropiperidyl Compound are disclosed herein.
式的化合物:
其中 Ar1、Ar2、X、R3 和 m 如本文所披露或其药学上可接受的盐("四氢哌啶化合物");包含有效量四氢哌啶化合物的组合物;以及治疗或预防疼痛、UI、溃疡、IBD、IBS、成瘾性疾病、帕金森病、帕金森氏症、焦虑症、癫痫、中风、癫痫发作、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限的方法、本文公开了四氢哌啶化合物在动物中的应用,包括向有需要的动物施用有效量的四氢哌啶化合物来治疗亨廷顿舞蹈症、肌萎缩性脊髓侧索硬化症、痴呆症、视网膜病变、肌肉痉挛、偏头痛、呕吐、运动障碍或抑郁症。